Ciltacabtagene autoleucel is a BCMA-directed CAR T-cell therapy used in the treatment of relapsed or refractory multiple myeloma in previously treated patients. Multiple myeloma is a malignancy involving the plasma cells of the bone marrow.
- Mechanism
- Curator reviewed · 3 references
Ciltacabtagene autoleucel is a chimeric antigen receptor (CAR) T-cell therapy in which genetically modified autologous T-cells are reprogrammed to target B-cell maturation antigen (BCMA), a biomarker of multiple myeloma. Patient peripheral blood mononuclear cells are obtained via leukapheresis, after which they are enriched for T-cells and genetically modified ex vivo to express a CAR comprising an anti-BCMA targeting domain consisting of two single-domain anti-BCMA antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain.
The genetically modified CAR T-cells are then expanded, washed, and cryopreserved for shipping back to the patient. When the product is infused back into the patient, the anti-BCMA CAR T-cells are able to recognize and eliminate BCMA-expressing target cells, including malignant plasma cells involved in multiple myeloma.
- Primary indication
- Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and...Curator reviewed · 4 structured indications
- First approval
- Canada, 2023 · United States, 2022 · European Union, 2022
- Also known as
- Cilta-cel · Ciltacel
- Code names
- JNJ-68284528 · LCAR-B38M · LCAR-B38M CAR-T cells
- Brand names
Resolves to
What you can answer from here — as of February 09, 2026
Which drugs share a target with Ciltacabtagene autoleucel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account